Linezolid-induced thrombocytopenia in impaired renal function: Is it time for a dose adjustment? A case report and review of literature

European Journal of Clinical Pharmacology

Volumn 70, Issue 1, 2014, Pages 23-28

  Cossu, A P ^a   Musu, M ^a   Mura, P ^a   De Giudici, L M ^a   Finco, G ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Acute kidney injury; Impaired renal function; Linezolid; Thrombocytopenia

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; DOBUTAMINE; DOPAMINE; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANURIA; AREA UNDER THE CURVE; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; ENDOTRACHEAL INTUBATION; FEMALE; HUMAN; HYPERCAPNIA; HYPOXIA; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LUNG INFECTION; MEDICAL LITERATURE; MEDLINE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONINVASIVE VENTILATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRACHEOBRONCHIAL TOILET;

ACETAMIDES; ANTI-BACTERIAL AGENTS; HUMANS; OXAZOLIDINONES; RENAL INSUFFICIENCY; THROMBOCYTOPENIA;

EID: 84891852526     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1585-6     Document Type: Review

References (32)

1. Parker RI (2012) Etiology and significance of thrombocytopenia in critically ill patients. Crit Care Clin 28:399-411
2. Loo AS, Gerzenhtein L, Ison MG (2012) Antimicrobial drug induced thrombocytopenia: a review of the literature. Semin Thromb Hemost 38:818-829
3. Spellberg B, Yoo T, Bayer AS (2004) Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 54:832-835 (Pubitemid 39386741)
4. Plachouras D, Giannitsioti E, Athanassia S et al (2006) No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 43:89-91
5. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ (2003) Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 37(4):517-520 (Pubitemid 36389660)
6. Green SL, Maddox JC, Huttenbach ED (2001) Linezolid and reversibile myelosuppression. JAMA 285:1291
7. Patel N, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP (2012) A comparative evaluation of adverse platelet outcomes among Veterans' Affairs patients receiving linezolid or vancomycin. J Antimicrob Chemother 67:727-735
8. Rao N, Ziran BH, Wagener MM et al (2004) Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis 38:1058-1064 (Pubitemid 38951248)
9. Nasraway SA, Shorr AF, Kuter DJ et al (2003) Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 37:1609-1616 (Pubitemid 37549946)
10. Kalil et al (2010) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 38(9):1802-1808
11. Krishnasam Z, Carlton D, Bimbo L et al (2002) Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 61:1136-1142 (Pubitemid 34175482)
12. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T (2009) Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 49:1071-1078
13. Whitehouse T, Cepeda JA, Shulman R et al (2005) Pharmacokinetic studies. Of linezolid and teicoplan in the critically ill. J Antimicrob Chemother 55:333-340 (Pubitemid 40425458)
14. Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K et al (2009) Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 33:98-99
15. Brier ME, Stalker DJ, Aronoff GR et al (2003) Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 47:2775-2780 (Pubitemid 37040247)
16. Fiaccadori E, Maggiore U, Rotelli C et al (2004) Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 32:2437-2442 (Pubitemid 39648225)
17. Tsuji Y, Hiraki Y, Mizoguchi A, Hayashi W, Kamohara R, Kamimura H et al (2008) Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 14:156-160 (Pubitemid 351624464)
18. Lin YH (2006) High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 28:345-351 (Pubitemid 44402995)
19. Wu VC et al (2006) High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42:66-72 (Pubitemid 41832082)
20. Kuter DJ, Tillotson GS (2001) Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid. Pharmacotherapy 21:1010-1013 (Pubitemid 32747320)
21. Attassi K, Hershberger E, Alam R, Zervos MJ (2002) Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34:695-698 (Pubitemid 34165334)
22. Sasaki et al (2011) Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 55:1867-1873
23. Matsumoto K et al (2010) Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 36:179-181
24. Tsuji Y et al (2011) Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 17:70-75
25. Hiraki Y et al (2011) Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci 342:456-460
26. Phizer (2008) ZIVOX (linezolid) label information, 2008. Retrieved June 20
27. Hiraki Y et al (2012) Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 44:60-64
28. Nukui Y et al (2013) High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 68(9):2128-2133
29. Taguchi K et al (2013) A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency. Scand J Infect Dis 45:77-80
30. Poulakos MN et al (2012) Probable linezolid-induced thrombocytopenia in a patient with vancomycin-resistant enterococci. J Pharm Pract 25(6):615-618
31. Lam S (2012) Linezolid-associated thrombocytopenia. Consult Pharm 27(7):504-508
32. Naranjo CA et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30(2):239-245 (Pubitemid 12149145)